These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

945 related articles for article (PubMed ID: 31166679)

  • 1. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
    Im SA; Lu YS; Bardia A; Harbeck N; Colleoni M; Franke F; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva-Vazquez R; Jung KH; Chakravartty A; Hughes G; Gounaris I; Rodriguez-Lorenc K; Taran T; Hurvitz S; Tripathy D
    N Engl J Med; 2019 Jul; 381(4):307-316. PubMed ID: 31166679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
    Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
    Slamon DJ; Neven P; Chia S; Fasching PA; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Esteva FJ; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Pivot X; Sondhi M; Wang Y; Chakravartty A; Rodriguez-Lorenc K; Taran T; Jerusalem G
    N Engl J Med; 2020 Feb; 382(6):514-524. PubMed ID: 31826360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
    Lu YS; Im SA; Colleoni M; Franke F; Bardia A; Cardoso F; Harbeck N; Hurvitz S; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; O'Regan R; Gasch C; Solovieff N; Wang C; Wang Y; Chakravartty A; Ji Y; Tripathy D
    Clin Cancer Res; 2022 Mar; 28(5):851-859. PubMed ID: 34965945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
    Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Hart L; Campone M; Petrakova K; Winer EP; Janni W; Conte P; Cameron DA; André F; Arteaga CL; Zarate JP; Chakravartty A; Taran T; Le Gac F; Serra P; O'Shaughnessy J
    N Engl J Med; 2022 Mar; 386(10):942-950. PubMed ID: 35263519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J
    N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
    Slamon DJ; Neven P; Chia S; Fasching PA; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Esteva FJ; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Pivot X; Vidam G; Wang Y; Rodriguez Lorenc K; Miller M; Taran T; Jerusalem G
    J Clin Oncol; 2018 Aug; 36(24):2465-2472. PubMed ID: 29860922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Petrakova K; Blackwell KL; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Mondal S; Su F; Miller M; Elmeliegy M; Germa C; O'Shaughnessy J
    Ann Oncol; 2018 Jul; 29(7):1541-1547. PubMed ID: 29718092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
    Slamon DJ; Neven P; Chia S; Jerusalem G; De Laurentiis M; Im S; Petrakova K; Valeria Bianchi G; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Ji Y; Wang C; Deore U; Chakravartty A; Zarate JP; Taran T; Fasching PA
    Ann Oncol; 2021 Aug; 32(8):1015-1024. PubMed ID: 34102253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 12. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
    Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
    Sonke GS; Hart LL; Campone M; Erdkamp F; Janni W; Verma S; Villanueva C; Jakobsen E; Alba E; Wist E; Favret AM; Bachelot T; Hegg R; Wheatley-Price P; Souami F; Sutradhar S; Miller M; Germa C; Burris HA
    Breast Cancer Res Treat; 2018 Feb; 167(3):659-669. PubMed ID: 29058175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
    Shah A; Bloomquist E; Tang S; Fu W; Bi Y; Liu Q; Yu J; Zhao P; Palmby TR; Goldberg KB; Chang CJG; Patel P; Alebachew E; Tilley A; Pierce WF; Ibrahim A; Blumenthal GM; Sridhara R; Beaver JA; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(13):2999-3004. PubMed ID: 29437768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
    Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
    Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
    Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
    Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
    Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
    Hortobagyi GN
    Breast Cancer Res; 2018 Oct; 20(1):123. PubMed ID: 30340505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
    Bardia A; Su F; Solovieff N; Im SA; Sohn J; Lee KS; Campos-Gomez S; Jung KH; Colleoni M; Vázquez RV; Franke F; Hurvitz S; Harbeck N; Chow L; Taran T; Rodriguez Lorenc K; Babbar N; Tripathy D; Lu YS
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34504990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.